# Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

> **NCT02558465** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2540 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT02558465
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-13
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-05-31
- **Target enrollment:** 2540 (ACTUAL)
- **Last updated:** 2022-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558465, "Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02558465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*